MannKind: Afrezza's slow start due to delays not demand for inhalable insulin
Sanofi's inhaled insulin drug Affrezza has generated lower than expected revenue due to marketing delays rather than low demand according to MannKind CFO, Matthew Pfeffer.
Archives for May 11, 2015
Upfront data analysis can improve study of protocol feasibility, expert says
Analyzing data on previous study performance and the complexity and design of a trial can offer earlier insights on whether a protocol is feasible, Michelle Marlborough, VP of product strategy at Medidata, told Outsourcing-Pharma.com.
Companies plead guilty to illegally sourcing, distributing pharmaceuticals in US
Toronto, Canada-based SB Medical Inc. and Barbados-based TC Medical Group, as well as Hanoch Stein of Baltimore plead guilty last week to a multi-year operation to smuggle and sell misbranded prescription pharmaceuticals and unlicensed wholesaling of...
Lilly builds drug delivery and device R&D site
Eli Lilly is building a drug delivery and device innovation centre in Cambridge, Massachusetts.